Berlin, Germany, August 29, 2013 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, announced today that Ben Lipps, designated CEO starting September 1st, 2013, has disclosed to the Company that he has bought 250,000 shares in MagForce, which represents 1.05% of the Company`s outstanding shares.
About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company`s proprietary, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For more information, please visit http://www.magforce.com.
Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.
Contact:
Anne Hennecke MC Services AG
T +49 89 210228-18 F +49 89 210228-88 M +49 151 12 555 759
Email: anne.hennecke@mc-services.eu
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Read more from the original source:
Voluntary Directors' Dealings announcement of Dr. Ben J. Lipps